argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
- Kroger cuts same-store sales outlook, keeps earnings guidance
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Morgan Stanley Positive on argenx SE (ARGX), 'Catalyst Driven Idea: CIDP Topline Readout'
January 5, 2023 4:04 PM ESTMorgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $450.00 price target on argenx SE (NASDAQ: ARGX)
The analyst comments "What and when is the catalyst? Efgartigimod Ph2 ADHERE trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is expected to readout in 1Q23 (NCT04281472). Readout is triggered after 88 relapse events occur in Stage B of the trial. Mgt. plans to report detailed topline data at a later date following the initial press release. The ADHERE trial is designed to test a subcutaneous (subQ) formulation of efgartigimod with a "Go/No-Go" decision... More
